Objective: to evaluate cilazapril in vasovagal syncope treatment. Method: eighty\|six cases of VVS patients found positive in TTT tilt were medicated with 2.5 mg cilazapril daily for three months and followed up by TT...Objective: to evaluate cilazapril in vasovagal syncope treatment. Method: eighty\|six cases of VVS patients found positive in TTT tilt were medicated with 2.5 mg cilazapril daily for three months and followed up by TTT. Results: seven cases quit due to cough or unexplained reason; 79 VVS patients had no more fainting spells; 75.95% of TTT results of patients changed to negative after 3 months therapy. The before and after cilazapril treatment average blood pressures (taken in lying position) were 121/73 mm Hg (1 mm Hg= 0.133kPa) and 120/76 mm Hg respectively ( P > 0.05); and mean heart rates were 68.63±12.37/min and 70.13±13.15/min respectively with no significant changes ( P > 0.05). Conclusion: Cilazapril was effective in treatment of VVS; did not affect normal blood pressure and heart rate; was safe; and had little side effect.展开更多
Recently, it has been found that atrial fibrillation (AF) is associated with renin angiotensin aldosterone system (RAAS) activation and that angiotensin converting enzyme inhibition (ACEI) reduces incidence of AF in ...Recently, it has been found that atrial fibrillation (AF) is associated with renin angiotensin aldosterone system (RAAS) activation and that angiotensin converting enzyme inhibition (ACEI) reduces incidence of AF in hypertensive patients. The relationship between ACEI and atrial remodelling in AF has been studied widely, but little is known about the mechanisms linking ACEI to thrombus formation in AF. Studies have shown that ACEI treatment can favourably influence endothelial dysfunction in hypertensive and heart failure patients and potentially modulate the fibrinolytic system in cardiopulmonary bypass patients. These data suggest that ACEI might influence the hypercoagulable state in AF. The objective of this study was to evaluate whether cilazapril, an ACEI, was conducive to hypercoagulated state in AF.展开更多
文摘Objective: to evaluate cilazapril in vasovagal syncope treatment. Method: eighty\|six cases of VVS patients found positive in TTT tilt were medicated with 2.5 mg cilazapril daily for three months and followed up by TTT. Results: seven cases quit due to cough or unexplained reason; 79 VVS patients had no more fainting spells; 75.95% of TTT results of patients changed to negative after 3 months therapy. The before and after cilazapril treatment average blood pressures (taken in lying position) were 121/73 mm Hg (1 mm Hg= 0.133kPa) and 120/76 mm Hg respectively ( P > 0.05); and mean heart rates were 68.63±12.37/min and 70.13±13.15/min respectively with no significant changes ( P > 0.05). Conclusion: Cilazapril was effective in treatment of VVS; did not affect normal blood pressure and heart rate; was safe; and had little side effect.
文摘Recently, it has been found that atrial fibrillation (AF) is associated with renin angiotensin aldosterone system (RAAS) activation and that angiotensin converting enzyme inhibition (ACEI) reduces incidence of AF in hypertensive patients. The relationship between ACEI and atrial remodelling in AF has been studied widely, but little is known about the mechanisms linking ACEI to thrombus formation in AF. Studies have shown that ACEI treatment can favourably influence endothelial dysfunction in hypertensive and heart failure patients and potentially modulate the fibrinolytic system in cardiopulmonary bypass patients. These data suggest that ACEI might influence the hypercoagulable state in AF. The objective of this study was to evaluate whether cilazapril, an ACEI, was conducive to hypercoagulated state in AF.
